S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
Log in

Becton, Dickinson and Stock Forecast, Price & News

-5.24 (-1.99 %)
(As of 01/14/2021 12:00 AM ET)
Today's Range
Now: $257.77
50-Day Range
MA: $245.70
52-Week Range
Now: $257.77
Volume1.37 million shs
Average Volume1.33 million shs
Market Capitalization$74.97 billion
P/E Ratio94.42
Dividend Yield1.26%
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Becton, Dickinson and logo


Overall MarketRank

1.96 out of 5 stars

Medical Sector

49th out of 1,479 stocks

Surgical & Medical Instruments Industry

10th out of 135 stocks

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment



Sales & Book Value

Annual Sales$17.12 billion
Cash Flow$17.93 per share
Book Value$81.98 per share


Net Income$874 million


Market Cap$74.97 billion
Next Earnings Date2/4/2021 (Estimated)
-5.24 (-1.99 %)
(As of 01/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Becton, Dickinson and (NYSE:BDX) Frequently Asked Questions

How has Becton, Dickinson and's stock price been impacted by COVID-19?

Becton, Dickinson and's stock was trading at $231.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BDX stock has increased by 11.2% and is now trading at $257.77.
View which stocks have been most impacted by COVID-19

Is Becton, Dickinson and a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Becton, Dickinson and stock.
View analyst ratings for Becton, Dickinson and
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Becton, Dickinson and?

Wall Street analysts have given Becton, Dickinson and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Becton, Dickinson and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Becton, Dickinson and's next earnings date?

Becton, Dickinson and is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Becton, Dickinson and

How were Becton, Dickinson and's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) announced its quarterly earnings results on Tuesday, November, 10th. The medical instruments supplier reported $2.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.52 by $0.27. The medical instruments supplier earned $4.78 billion during the quarter, compared to the consensus estimate of $4.48 billion. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The company's revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.31 earnings per share.
View Becton, Dickinson and's earnings history

How often does Becton, Dickinson and pay dividends? What is the dividend yield for Becton, Dickinson and?

Becton, Dickinson and declared a quarterly dividend on Tuesday, November 24th. Investors of record on Thursday, December 10th will be given a dividend of $0.83 per share on Thursday, December 31st. This represents a $3.32 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend is Wednesday, December 9th. This is a positive change from Becton, Dickinson and's previous quarterly dividend of $0.79.
View Becton, Dickinson and's dividend history

Is Becton, Dickinson and a good dividend stock?

Becton, Dickinson and pays an annual dividend of $3.32 per share and currently has a dividend yield of 1.26%. Becton, Dickinson and has been increasing its dividend for 48 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Becton, Dickinson and is 32.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Becton, Dickinson and will have a dividend payout ratio of 24.79% next year. This indicates that Becton, Dickinson and will be able to sustain or increase its dividend.
View Becton, Dickinson and's dividend history.

What guidance has Becton, Dickinson and issued on next quarter's earnings?

Becton, Dickinson and issued an update on its first quarter 2021 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.308-5.308 billion, compared to the consensus revenue estimate of $4.69 billion.

What price target have analysts set for BDX?

14 analysts have issued 12 month price objectives for Becton, Dickinson and's stock. Their forecasts range from $260.00 to $300.00. On average, they anticipate Becton, Dickinson and's share price to reach $281.08 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price.
View analysts' price targets for Becton, Dickinson and
or view Wall Street analyst' top-rated stocks.

Who are some of Becton, Dickinson and's key competitors?

What other stocks do shareholders of Becton, Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), The Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Becton, Dickinson and's key executives?

Becton, Dickinson and's management team includes the following people:
  • Mr. Vincent A. Forlenza, Exec. Chairman (Age 67, Pay $2.51M)
  • Mr. Thomas E. Polen Jr., Pres, CEO & Director (Age 47, Pay $2.11M)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 63, Pay $1.4M)
  • Mr. Samrat S. Khichi, Exec. VP of Regulatory & Gov. Affairs and Gen. Counsel (Age 53, Pay $2.19M)
  • Mr. Alberto Mas, Exec. VP & Pres of the Medical Segment (Age 59, Pay $1.15M)
  • Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 57, Pay $1.95M)
  • Mr. Thomas J. Spoerel, VP, Controller & Chief Accounting Officer (Age 42)
  • Mr. Charles R. Bodner, Sr. VP of Corp. Fin. (Age 49)
  • Dr. John A. DeFord, Exec. VP of R&D and CTO (Age 58)
  • Jerry Flasz, Exec. VP of Global Services & Chief Information Officer

What is Becton, Dickinson and's stock symbol?

Becton, Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton, Dickinson and's major shareholders?

Becton, Dickinson and's stock is owned by many different retail and institutional investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.23%), Cacti Asset Management LLC (0.07%), Tandem Investment Advisors Inc. (0.05%), State of Alaska Department of Revenue (0.02%), Jacobs & Co. CA (0.02%) and Huntington National Bank (0.01%). Company insiders that own Becton, Dickinson and stock include Alexandre Conroy, Betty D Larson, Catherine M Burzik, Charles R Bodner, Claire Fraser, James C Lim, Patrick Kaltenbach, Ribo Alberto Mas, Roland Goette, Samrat S Khichi, Simon D Campion, Thomas J Spoerel and Vincent A Forlenza.
View institutional ownership trends for Becton, Dickinson and

Which major investors are selling Becton, Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including James Hambro & Partners, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, First Hawaiian Bank, Huntington National Bank, Bath Savings Trust Co, State of Alaska Department of Revenue, Investment House LLC, and Access Financial Services Inc.. Company insiders that have sold Becton, Dickinson and company stock in the last year include Claire Fraser, Patrick Kaltenbach, Roland Goette, Simon D Campion, and Vincent A Forlenza.
View insider buying and selling activity for Becton, Dickinson and
or view top insider-selling stocks.

Which major investors are buying Becton, Dickinson and stock?

BDX stock was acquired by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., IFM Investors Pty Ltd, Louisiana State Employees Retirement System, Creative Financial Designs Inc. ADV, Donaldson Capital Management LLC, Pure Financial Advisors Inc., Charles Schwab Trust Co, and Arlington Partners LLC.
View insider buying and selling activity for Becton, Dickinson and
or or view top insider-buying stocks.

How do I buy shares of Becton, Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Becton, Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $257.77.

How big of a company is Becton, Dickinson and?

Becton, Dickinson and has a market capitalization of $74.97 billion and generates $17.12 billion in revenue each year. The medical instruments supplier earns $874 million in net income (profit) each year or $10.20 on an earnings per share basis. Becton, Dickinson and employs 65,000 workers across the globe.

What is Becton, Dickinson and's official website?

The official website for Becton, Dickinson and is www.bd.com.

How can I contact Becton, Dickinson and?

Becton, Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.